Hepta Studies Target MASH Treatment Decisions With Blood Testing
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Hepta, a company focused on liver disease, says its experimental blood test, LiquidTransformer, performed as well as magnetic resonance elastography, a specialized scan, at picking…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
4 confirmed facts, 2 open questions and 2 sources behind this story.